NovoCure (NASDAQ:NVCR) Announces Earnings Results, Beats Expectations By $0.20 EPS

NovoCure (NASDAQ:NVCR) announced its earnings results on Thursday. The medical equipment provider reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.20, FiscalAI reports. The firm had revenue of $183.58 million for the quarter, compared to analysts’ expectations of $172.44 million. NovoCure had a negative return on equity of 50.82% and a negative net margin of 25.66%.NovoCure’s quarterly revenue was up 15.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.36) EPS.

Here are the key takeaways from NovoCure’s conference call:

• NovoCure posted its strongest commercial quarter to date, with Q2 revenue of $184 million up 16% year over year and adjusted EBITDA turning positive at $11 million.
• Optune Gio remained the core growth driver, ending the quarter with 4,636 active patients on therapy, up 11% year over year, with particularly strong growth in the U.S., Germany, Japan, and global markets.
• Optune Pax launch momentum continued in locally advanced pancreatic cancer, with 418 prescriptions and 285 patients on therapy at quarter-end; management said adoption is broadening across community and academic sites and repeat prescribing is increasing.
• Management received CE Mark for Optune Pax in Europe and has begun Germany labeling, registration, and prescriber certification, but expects reimbursement and hospital contracting to make the ramp slower than in the U.S.
• The company raised full-year guidance to $710 million-$725 million in revenue and $0-$15 million in adjusted EBITDA, while also saying it now expects to reach full-year 2026 adjusted EBITDA breakeven.
• NovoCure is refocusing R&D around pancreatic cancer and broader label expansion, including an upcoming IDE trial with divarasib/RAS inhibitors, while trimming LUNAR-2 spend by about $90 million to support profitability goals.

NovoCure Trading Down 7.1%

NASDAQ:NVCR traded down $1.42 during mid-day trading on Friday, reaching $18.57. The company’s stock had a trading volume of 1,002,799 shares, compared to its average volume of 1,781,598. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.90 and a quick ratio of 2.70. The stock has a market cap of $2.15 billion, a P/E ratio of -12.15 and a beta of 0.94. The company’s fifty day simple moving average is $16.64 and its two-hundred day simple moving average is $14.12. NovoCure has a twelve month low of $9.82 and a twelve month high of $21.45.

Insider Activity at NovoCure

In related news, Director Timothy J. Scannell sold 2,945 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total transaction of $46,442.65. Following the completion of the transaction, the director owned 14,288 shares of the company’s stock, valued at approximately $225,321.76. This represents a 17.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Frank X. Leonard sold 34,273 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $17.93, for a total transaction of $614,514.89. Following the transaction, the chief executive officer directly owned 459,520 shares in the company, valued at approximately $8,239,193.60. This represents a 6.94% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 51,943 shares of company stock worth $893,171. Corporate insiders own 5.52% of the company’s stock.

Institutional Investors Weigh In On NovoCure

Institutional investors have recently added to or reduced their stakes in the company. Alliancebernstein L.P. raised its stake in NovoCure by 0.8% during the third quarter. Alliancebernstein L.P. now owns 137,106 shares of the medical equipment provider’s stock valued at $1,771,000 after buying an additional 1,076 shares in the last quarter. Royal Bank of Canada lifted its position in NovoCure by 14.9% in the 4th quarter. Royal Bank of Canada now owns 12,830 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 1,667 shares during the last quarter. LPL Financial LLC grew its holdings in NovoCure by 15.1% in the 4th quarter. LPL Financial LLC now owns 16,380 shares of the medical equipment provider’s stock worth $212,000 after buying an additional 2,153 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of NovoCure by 3.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,992 shares of the medical equipment provider’s stock worth $1,336,000 after purchasing an additional 2,502 shares in the last quarter. Finally, Empowered Funds LLC bought a new stake in shares of NovoCure during the fourth quarter valued at about $33,000. Hedge funds and other institutional investors own 84.61% of the company’s stock.

Key Stories Impacting NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: NovoCure reported Q2 earnings of -$0.13 per share, beating expectations for a larger loss, while revenue of $183.58 million also topped estimates and rose 15.6% year over year. The results suggest improving execution and stronger demand. Article Title
• Positive Sentiment: The company raised its FY2026 revenue guidance to $710 million-$725 million, above the Street’s prior expectation, reinforcing confidence in near-term growth.
• Positive Sentiment: Investor sentiment was boosted by reports that Novocure hit a new 52-week high as traders positioned for a higher growth outlook and potential FDA approval for its brain therapy candidate. Article Title
• Neutral Sentiment: HC Wainwright trimmed its FY2029 EPS estimate slightly to $1.90 from $1.95, but kept a Buy rating and raised its price target to $52, which still signals long-term upside. Article Title
• Neutral Sentiment: Wedbush also lifted its price target, from $18 to $20, while maintaining a Neutral rating, reflecting a more cautious stance despite recent strength. Article Title

Analysts Set New Price Targets

A number of analysts recently commented on NVCR shares. Wells Fargo & Company increased their price objective on NovoCure from $13.50 to $17.00 and gave the company an “equal weight” rating in a research note on Monday, May 4th. Wedbush lifted their price target on shares of NovoCure from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Friday. HC Wainwright set a $32.00 price objective on shares of NovoCure in a research report on Friday. Zacks Research downgraded shares of NovoCure from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Finally, JPMorgan Chase & Co. initiated coverage on shares of NovoCure in a research report on Monday, July 13th. They set a “neutral” rating and a $17.00 target price on the stock. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $21.20.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.